Abstract 2079P
Background
We aimed to evaluate the efficacy and safety of naloxegol for opioid-induced constipation (OIC) in cancer patients in a real-life setting.
Methods
We pooled individual patient data from three multicenter observational studies conducted with naloxegol in cancer population. Efficacy outcomes included: response rate at week 4 (≥3 spontaneous bowel movements [SBM] per week and an increase of ≥1 from baseline); clinically relevant improvement (>0.5 points) in the Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) and in the Patient Assessment of Constipation Symptoms (PAC-SYM); and clinically relevant improvement in the Bowel Function Index (BFI ≥ 12 points at the endpoint). All analyses were performed using a visitwise approach. Homogeneity was assessed with Cochran's Q test.
Results
393/427 patients were included in the pooled efficacy/safety analyses, with a median age of 64 years and a slight predominance of males (53%). Lung (25%), breast (18%), prostate (9%) and head & neck (6%) were the most common tumor locations. 66% of the patients had metastases, and 53% were receiving chemotherapy. The most common opioids were fentanyl (43%), oxycodone (39%) and morphine (28%), with a median treatment duration of 8.9 weeks. Most patients (83%) received an initial dose of naloxegol of 25 mg and 86% were receiving laxatives at baseline. Efficacy outcomes are presented in the table. Twenty-six (6%) of the 427 patients discontinued treatment due to adverse reactions and 3 (0.7%) patients reported serious adverse reactions. Table: 2079P
Summary of efficacy results
Kyonal | Move | Nacasy | Pooled | Cochran’s Q (p-value) | |
SBM response rate | 94/126 (75%) | 58/79 (73%) | 71/109 (65%) | 223/314 (71%) [95%CI 66-76] | 2.75 (0.250) |
Responders in QoL (PAC-QOL) | 69/113 (61%) | 44/75 (59%) | 66/111 (60%) | 179/299 (60%) [95%CI 54-66] | 0.12 (0.940) |
Responders in constipation symptoms (PAC-SYM) | 79/115 (69%) | 52/75 (69%) | NR | 131/190 (69%)[95%CI 62-76] | 0.01 (0.930) |
Responders in constipation symptoms (BFI) | NR | 58/79 (73%) | 75/116 (65%) | 133/195 (68%)[95%CI 62-75] | 1.70 (0.190) |
Conclusions
Treatment with naloxegol for the OIC in patients with cancer pain in the real-world setting resulted in a high proportion of responders in the SBM and consistently relevant improvements in the quality of life and constipation symptoms. Naloxegol was well tolerated and safe.
Clinical trial identification
Editorial acknowledgement
Fernando Rico-Villademoros (Apices).
Legal entity responsible for the study
Kyowa Kirin.
Funding
Kyowa Kirin.
Disclosure
M.D.C. Beato Zambrano: Financial Interests, Institutional, Advisory Board: Servier, Leo Pharma, Kyowa Kirin; Financial Interests, Institutional, Research Grant: BMS. A. Lemaire: Financial Interests, Personal, Advisory Board: Kyowa Kirin, Alfasigma; Financial Interests, Personal, Training: Ethypharm. V. Montesarchio: Financial Interests, Institutional, Advisory Board: Amgen S.p.A, Servier, Leo Pharma; Non-Financial Interests, Institutional, Local PI: BMS, Merck, Amgen. J. Sabate: Financial Interests, Personal, Invited Speaker: Mayoly Spindler, Biocodex, SChär, Servier, Tillots, Norgine, Novozymes/Précision Biotics, Kyowa Kirin; Financial Interests, Personal, Advisory Board: Biocodex, Norgine, Novozymes/Précision Biotics, Kyowa Kirin; Financial Interests, Personal, Speaker, Consultant, Advisor: Biocodex, Norgine, Novozymes/Précision Biotics, Kyowa Kirin. J. Serna i Mont-Ros: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Medtronic. R. Namane: Financial Interests, Personal, Full or part-time Employment: Kyowa Kirin. S. Martín Baccarelli: Financial Interests, Institutional, Research Funding: Kyowa Kirin. F. Rico-Villademoros: Financial Interests, Institutional, Writing Engagement: Kyowa Kirin. All other authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06